{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Athenex, Inc."},"Symbol":{"label":"Symbol","value":"ATNX"},"Address":{"label":"Address","value":"1001 MAIN STREET SUITE 600, BUFFALO, New York, 14203, United States"},"Phone":{"label":"Phone","value":"+1 716 427-2950"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities."},"CompanyUrl":{"label":"Company Url","value":"https://www.athenex.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Darrel P. Cohen","title":"Chief Medical Officer"},{"name":"Jeffrey M. Yordon","title":"COO &amp; President-Athenex Pharmaceutical Division"},{"name":"Michael Smolinski","title":"Chief Scientific Officer"},{"name":"Yiu Nam Lau","title":"Chairman &amp; Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}